Hope S. Rugo, MD

Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.

Related Items
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
Alpelisib First Drug to Improve Outcomes in Advanced Breast Cancer with PIK3CA Mutation
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer
5-mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
JHOP Web Exclusives published on January 28, 2019 in Breast Cancer
Omega-3 Fatty Acids Significantly Reduced Pain in Obese Patients with Breast Cancer
Meg Barbor, MPH
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Breast Cancer
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
The Navigator's Role in Genetic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Why Are Clinical Trials Important?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Educating Oncology Professionals on Genetic and Genomic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Last modified: March 9, 2018